WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002026758) OLIGONUCLEOTIDE MODULATION OF HER-1 EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/026758    International Application No.:    PCT/US2001/030551
Publication Date: 04.04.2002 International Filing Date: 28.09.2001
Chapter 2 Demand Filed:    24.04.2002    
IPC:
A61K 38/00 (2006.01), A61K 48/00 (2006.01), C12N 15/11 (2006.01)
Applicants: ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US) (For All Designated States Except US).
BENNETT, C., Frank [US/US]; (US) (For US Only).
WYATT, Jacqueline, R. [US/US]; (US) (For US Only).
FREIER, Susan, M. [US/US]; (US) (For US Only)
Inventors: BENNETT, C., Frank; (US).
WYATT, Jacqueline, R.; (US).
FREIER, Susan, M.; (US)
Agent: LICATA, Jane, Massey; Licata & Tyrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US)
Priority Data:
09/676,610 29.09.2000 US
Title (EN) OLIGONUCLEOTIDE MODULATION OF HER-1 EXPRESSION
(FR) MODULATION OLIGONUCLEOTIDIQUE DE L'EXPRESSION DU RECEPTEUR HER-1
Abstract: front page image
(EN)Compounds, compositions and methods are provided for inhibiting the expressionof human Her-1. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding Her-1. Methods of using these oligonucleotides for inhibition of Her-1 expression and for treatment of diseases such as cancers associated with overexpression of Her-1 are provided.
(FR)L'invention concerne des composés, des compositions et des méthodes d'inhibition de l'expression du récepteur Her-1 humain. Les compositions comprennent des oligonucléotides complémentaires à l'ARNm ciblés sur des acides nucléiques codant pour le récepteur Her-1. L'invention concerne également des méthodes d'utilisation de ces oligonucléotides dans l'inhibition de l'expression du récepteur Her-1 et dans le traitement des maladies telles que les cancers associés à la surexpression du Her-1.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)